Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell.
CAR T cell
cytotoxicity
fluorescent proteins
immunodeficiency virus
real-time
Journal
AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
30
9
2020
medline:
31
7
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
The success of chimeric antigen receptor (CAR) T cell therapies for treating leukemia has resulted in a booming interest for the technology. Expression of a CAR in T cells allows redirection of their natural cytolytic activity toward cells presenting a specific designated surface antigen. Although CAR T cell therapies have thus far shown promising results mostly in B cell malignancy trials, interest in their potential to treat other diseases is on the rise, including using CAR T cells to control human immunodeficiency virus infection. The assessment of CAR T cell potency toward specific targets
Identifiants
pubmed: 32988211
doi: 10.1089/AID.2020.0163
pmc: PMC7703091
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
998-1009Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI126623
Pays : United States
Références
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
pubmed: 9371822
J Immunol. 2007 Sep 15;179(6):3812-20
pubmed: 17785818
Immunology. 1968 Feb;14(2):181-96
pubmed: 4966657
J Virol. 2016 Jul 11;90(15):6999-7006
pubmed: 27226366
Blood Rev. 2016 May;30(3):157-67
pubmed: 26574053
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Blood. 2000 Jul 15;96(2):467-74
pubmed: 10887107
J Immunol Methods. 1983 Nov 25;64(3):313-20
pubmed: 6199426
Mol Ther. 2010 Apr;18(4):725-33
pubmed: 19997089
J Immunol Methods. 2001 Mar 1;249(1-2):99-110
pubmed: 11226468
J Immunol Methods. 2013 May 31;391(1-2):174-8
pubmed: 23500782
Sci Rep. 2018 Jan 9;8(1):199
pubmed: 29317736
J Immunol Methods. 1997 Aug 22;207(1):43-51
pubmed: 9328585
Front Immunol. 2018 Mar 20;9:492
pubmed: 29616024
Eur J Immunol. 2018 Jun;48(6):898-914
pubmed: 29427516
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Immunol Rev. 2014 Jan;257(1):127-44
pubmed: 24329794
PLoS One. 2018 Mar 2;13(3):e0193498
pubmed: 29499048
Cytotherapy. 2018 Mar;20(3):407-419
pubmed: 29306566
Nat Biotechnol. 2008 Jul;26(7):808-16
pubmed: 18587387
PLoS Pathog. 2016 Apr 11;12(4):e1005537
pubmed: 27064278
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Cytometry A. 2008 Nov;73(11):1050-7
pubmed: 18615597
Blood. 2014 Apr 24;123(17):2625-35
pubmed: 24578504
Front Immunol. 2019 Sep 27;10:2310
pubmed: 31611880
Biol Proced Online. 2003;5:182-188
pubmed: 14615814
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Immunol Rev. 2015 Jan;263(1):68-89
pubmed: 25510272
Enferm Infecc Microbiol Clin. 2010 Apr;28(4):245-52
pubmed: 19783328
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
Blood. 2004 Jun 1;103(11):4062-9
pubmed: 14976042
J Immunol Methods. 2019 Nov;474:112668
pubmed: 31525367
Intervirology. 2002;45(4-6):290-9
pubmed: 12566712
J Virol. 2004 Jan;78(2):568-75
pubmed: 14694088
J Immunol Methods. 1997 May 12;204(1):89-98
pubmed: 9202713
J Virol. 2004 Oct;78(19):10588-97
pubmed: 15367626